$78 Million

Oncopeptides AB


Bookrunner, June 2019

Oncopeptides AB
Directed Share Issue

Oncopeptides is a late clinical-stage biotechnology company focused on the development of targeted cancer therapies, with an initial focus on multiple myeloma (MM). The Company’s lead candidate, melflufen, a novel, peptide-conjugated alkylator belonging to a new class called peptidase enhanced compounds (PEnC), works by eliciting increased cytotoxicity in MM cells.